デフォルト表紙
市場調査レポート
商品コード
1621513

セラノスティクス市場:製品、用途、エンドユーザー別-2025-2030年の世界予測

Theranostics Market by Product (Product, Services, Software), Application (Bone Metastatis, Cardiovascular Diseases, Lymphoma), End-User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
セラノスティクス市場:製品、用途、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

セラノスティクス市場は、2023年に23億3,000万米ドルと評価され、2024年には26億7,000万米ドルに達すると予測され、CAGR 14.89%で成長し、2030年には61億8,000万米ドルに達すると予測されています。

セラノスティクスはTherapeutics(治療)とDiagnostics(診断)の合成語で、個別化医療を大きく前進させるものであり、標的治療戦略を提供すると同時に、診断検査によって治療効果をモニタリングすることを目的としています。この2つのアプローチは、個々の患者のプロファイルに合わせたより正確な医療介入の必要性に対応し、治療結果を改善し、副作用を最小限に抑えます。セラノスティクスの用途は主に腫瘍学、心臓病学、神経学に及び、最終用途は病院、診断研究所、専門クリニックに及んでいます。市場成長に影響を与える主な要因としては、ゲノムおよび精密医療の進歩、慢性疾患の有病率の増加、個別化治療に対する需要の高まりなどが挙げられます。診断精度を高め、治療モニタリングを合理化するための人工知能と機械学習の統合には、最新の潜在的機会が存在します。しかし、高い開発コスト、複雑な規制のハードル、限られた償還の枠組みといった制約が、市場拡大の課題となっています。さらに、技術革新は知的財産の問題や、セラノスティック・アプローチの有効性を裏付ける確固たる臨床エビデンスの必要性によって阻害されることが多いです。こうした課題にもかかわらず、この市場は、特にマルチモーダルイメージング剤の開発、放射性医薬品アプリケーションの強化、様々な疾患に対する新規バイオマーカーの探索など、技術革新のための肥沃な土壌を提供しています。企業は、研究開発協力に投資し、費用対効果の高いソリューションに注力し、有利な規制政策を提唱することで、成長を促進することができます。市場力学はダイナミックに進化しており、技術の進歩や個別化医療戦略の重視の高まりがその原動力となっています。この動向を利用しようとする企業は、新しいテクノロジーへの機敏な対応を優先し、研究拡大のための学術機関とのパートナーシップを促進し、戦略的マーケティングに取り組んで、ヘルスケア専門家と患者の間でセラノスティクスの利点についての認識と教育を強化する必要があります。これらの戦略は、課題を克服し、急成長するこの分野で確固たる地位を築くための一助となると思われます。

主な市場の統計
基準年[2023] 23億3,000万米ドル
推定年[2024] 26億7,000万米ドル
予測年[2030] 61億8,000万米ドル
CAGR(%) 14.89%

市場力学:急速に進化するセラノスティクス市場の主要市場インサイトを公開

セラノスティクス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 対象疾患の世界の流行
    • 個別化医療と分子生物学の進歩の高まり
  • 市場抑制要因
    • 研究開発に伴う高コストと規制当局の承認の複雑さ
  • 市場機会
    • セラノスティクスにおけるデータ分析と機械学習の統合の増加
    • 新規バイオマーカーと非侵襲的イメージング技術の開発拡大
  • 市場の課題
    • データプライバシーと個別化医療の倫理的配慮

ポーターのファイブフォース:セラノスティクス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:セラノスティクス市場における外部からの影響の把握

外部マクロ環境要因は、セラノスティクス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析セラノスティクス市場における競合情勢の把握

セラノスティクス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスセラノスティクス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、セラノスティクス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨セラノスティクス市場における成功への道筋を描く

セラノスティクス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 対象疾患の蔓延が世界的に増加
      • 個別化医療と分子生物学の進歩
    • 抑制要因
      • 研究開発にかかるコストの高さと規制承認の複雑さ
    • 機会
      • セラノスティクスにおけるデータ分析と機械学習の統合の強化
      • 新しいバイオマーカーと非侵襲的イメージング技術の開発が進む
    • 課題
      • データプライバシーと個別化医療の倫理的配慮
  • 市場セグメンテーション分析
    • 製品:データの取得、処理、分析のためのソフトウェアの使用の増加
    • エンドユーザー:さまざまな疾患の管理における病院におけるセラノスティクスの潜在的可能性の拡大
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 セラノスティクス市場:製品別

  • 製品
    • 診断画像
      • 機能イメージング
      • 分子イメージング
      • 核イメージング
    • 体外診断/バイオマーカースクリーニング
      • 蛍光in situハイブリダイゼーション
      • 次世代シーケンシング
      • ポリメラーゼ連鎖反応
    • 放射性医薬品
      • フッ素18
      • ガリウム68
      • ヨウ素131
      • ルテチウム177
      • ラジウム223
      • サマリウム153
      • ストロンチウム89
      • テクネチウム99
      • イットリウム90
  • サービス
  • ソフトウェア
    • 画像解析
    • 予測モデリング

第7章 セラノスティクス市場:用途別

  • 骨転移
  • 心血管疾患
  • リンパ腫
  • 神経内分泌腫瘍
  • 前立腺がん

第8章 セラノスティクス市場:エンドユーザー別

  • がんケアセンター
  • 病院
  • 調査・学術センター
  • セラノスティクスセンター

第9章 南北アメリカのセラノスティクス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のセラノスティクス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのセラノスティクス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • クラリティ社の前立腺がん治療薬臨床試験、最高用量レベルコホートで進展
    • BAMF HealthとGEヘルスケアが協力し、セラノスティクスの成長に向けた持続可能でスケーラブルなソリューションを実現
    • UCLAヘルスがセラノスティクスセンターを開設
  • 戦略分析と提言

企業一覧

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMerieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Invicro, LLC
  • Ipsen Pharma
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
  • United Theranostics
図表

LIST OF FIGURES

  • FIGURE 1. THERANOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. THERANOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERANOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY FUNCTIONAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY LODINE-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY SAMARIUM-153, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY STRONTIUM-89, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNETIUM-99, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY BONE METASTATIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY THERANOSTICS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 357. TURKEY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 359. TURKEY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 360. TURKEY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. TURKEY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 362. TURKEY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES THERANOSTICS
目次
Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 2.33 billion in 2023, expected to reach USD 2.67 billion in 2024, and is projected to grow at a CAGR of 14.89%, to USD 6.18 billion by 2030.

Theranostics, a portmanteau of therapeutics and diagnostics, represents a significant advancement in personalized medicine, aiming to offer targeted treatment strategies while simultaneously monitoring the therapy's efficacy through diagnostic tests. This dual approach addresses the necessity for more precise medical interventions tailored to individual patient profiles, improving treatment outcomes and minimizing adverse effects. The application of theranostics predominantly spans oncology, cardiology, and neurology, with end-use extending across hospital settings, diagnostic laboratories, and specialty clinics. Key factors influencing market growth include advancements in genomics and precision medicine, increasing prevalence of chronic diseases, and rising demand for personalized treatments. The latest potential opportunities exist in the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and streamline therapeutic monitoring. However, limitations such as high development costs, complex regulatory hurdles, and limited reimbursement frameworks pose challenges to market expansion. Furthermore, technological innovations are often impeded by intellectual property issues and a need for robust clinical evidence to support the efficacy of theranostic approaches. Despite these challenges, the market offers fertile ground for innovation, particularly in developing multimodal imaging agents, enhancing radiopharmaceutical applications, and exploring novel biomarkers for various diseases. Businesses can foster growth by investing in R&D collaborations, focusing on cost-effective solutions, and advocating for favorable regulatory policies. The nature of the theranostics market is dynamic and evolving, driven by technological advancements and an increasing emphasis on personalized care strategies. Companies looking to capitalize on this trend should prioritize agile adaptation to emerging technologies, foster partnerships with academic institutions for research expansion, and engage in strategic marketing to enhance awareness and education about theranostics' benefits among healthcare professionals and patients alike. These strategies can help navigate the challenges and position businesses to ground themselves firmly in this burgeoning field.

KEY MARKET STATISTICS
Base Year [2023] USD 2.33 billion
Estimated Year [2024] USD 2.67 billion
Forecast Year [2030] USD 6.18 billion
CAGR (%) 14.89%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Theranostics Market

The Theranostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of target diseases globally
    • Rising advancements in personalized medicine and molecular biology
  • Market Restraints
    • High costs associated with R&D and the complexity of regulatory approvals
  • Market Opportunities
    • Increasing integration of data analytics and machine learning in theranostics
    • Growing development of novel biomarkers and non-invasive imaging techniques
  • Market Challenges
    • Data privacy and the ethical considerations of personalized medicine

Porter's Five Forces: A Strategic Tool for Navigating the Theranostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Theranostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Theranostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Theranostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Theranostics Market

A detailed market share analysis in the Theranostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Theranostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Theranostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Theranostics Market

A strategic analysis of the Theranostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Theranostics Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Ariceum Therapeutics GmbH, Astellas Pharma Inc., BAMF Health, Bayer AG, bioMerieux SA, Biosynth Ltd., Cardinal Health, Inc., Cerebral Therapeutics, Inc., Clarity Pharmaceuticals, Curasight A/S, Curium Inc., Evergreen Theragnostics, Inc., GE HealthCare Technologies, Inc., Hermes Medical Solutions AB, Icon Group, Indi Molecular, Inc., Integrated Clinical Oncology Network Pty Ltd., Invicro, LLC, Ipsen Pharma, Radiopharm Theranostics Limited, Ratio Therapeutics, Siemens Healthineers AG, SOFIE Co., Telix Pharmaceuticals Limited, and United Theranostics.

Market Segmentation & Coverage

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Product, Services, and Software. The Product is further studied across Diagnostic Imaging, In Vitro Diagnostics/Biomarker Screening, and Radiopharmaceuticals. The Diagnostic Imaging is further studied across Functional Imaging, Molecular Imaging, and Nuclear Imaging. The In Vitro Diagnostics/Biomarker Screening is further studied across Fluorescence In Situ Hybridization, Next-generation Sequencing, and Polymerase Chain Reaction. The Radiopharmaceuticals is further studied across Fluorine-18, Gallium-68, lodine-131, Lutetium-177, Radium-223, Samarium-153, Strontium-89, Technetium-99, and Yttrium-90. The Software is further studied across Imaging Analytics and Predictive Modeling.
  • Based on Application, market is studied across Bone Metastatis, Cardiovascular Diseases, Lymphoma, Neuroendocrine Tumors, and Prostate Cancer.
  • Based on End-User, market is studied across Cancer Care Centers, Hospitals, Research & Academic Centers, and Theranostics Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of target diseases globally
      • 5.1.1.2. Rising advancements in personalized medicine and molecular biology
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and the complexity of regulatory approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing integration of data analytics and machine learning in theranostics
      • 5.1.3.2. Growing development of novel biomarkers and non-invasive imaging techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and the ethical considerations of personalized medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising usage of software for data acquisition, processing, and analysis
    • 5.2.2. End-User: Growing potential of theranostics among hospitals for the management of a variety of diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Theranostics Market, by Product

  • 6.1. Introduction
  • 6.2. Product
    • 6.2.1. Diagnostic Imaging
      • 6.2.1.1. Functional Imaging
      • 6.2.1.2. Molecular Imaging
      • 6.2.1.3. Nuclear Imaging
    • 6.2.2. In Vitro Diagnostics/Biomarker Screening
      • 6.2.2.1. Fluorescence In Situ Hybridization
      • 6.2.2.2. Next-generation Sequencing
      • 6.2.2.3. Polymerase Chain Reaction
    • 6.2.3. Radiopharmaceuticals
      • 6.2.3.1. Fluorine-18
      • 6.2.3.2. Gallium-68
      • 6.2.3.3. lodine-131
      • 6.2.3.4. Lutetium-177
      • 6.2.3.5. Radium-223
      • 6.2.3.6. Samarium-153
      • 6.2.3.7. Strontium-89
      • 6.2.3.8. Technetium-99
      • 6.2.3.9. Yttrium-90
  • 6.3. Services
  • 6.4. Software
    • 6.4.1. Imaging Analytics
    • 6.4.2. Predictive Modeling

7. Theranostics Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastatis
  • 7.3. Cardiovascular Diseases
  • 7.4. Lymphoma
  • 7.5. Neuroendocrine Tumors
  • 7.6. Prostate Cancer

8. Theranostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Care Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Centers
  • 8.5. Theranostics Centers

9. Americas Theranostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Theranostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Theranostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
    • 12.3.2. BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics
    • 12.3.3. UCLA Health to Open Theranostics Center
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Ariceum Therapeutics GmbH
  • 3. Astellas Pharma Inc.
  • 4. BAMF Health
  • 5. Bayer AG
  • 6. bioMerieux SA
  • 7. Biosynth Ltd.
  • 8. Cardinal Health, Inc.
  • 9. Cerebral Therapeutics, Inc.
  • 10. Clarity Pharmaceuticals
  • 11. Curasight A/S
  • 12. Curium Inc.
  • 13. Evergreen Theragnostics, Inc.
  • 14. GE HealthCare Technologies, Inc.
  • 15. Hermes Medical Solutions AB
  • 16. Icon Group
  • 17. Indi Molecular, Inc.
  • 18. Integrated Clinical Oncology Network Pty Ltd.
  • 19. Invicro, LLC
  • 20. Ipsen Pharma
  • 21. Radiopharm Theranostics Limited
  • 22. Ratio Therapeutics
  • 23. Siemens Healthineers AG
  • 24. SOFIE Co.
  • 25. Telix Pharmaceuticals Limited
  • 26. United Theranostics